Ticker reaction data · Health Care

Johnson & Johnson (JNJ)

JNJ moved a median of +0.06% 30 minutes after news, and +0.06% by the close. How JNJ actually reacts to news — the realized, point-in-time move the market made, measured across 2,000+ labeled events over the last three years with zero look-ahead.

The quantified answer

JNJ’s median reaction, across the day.

+0.06%
Median 30-min
Typical reaction 30 minutes after any JNJ news
56%
Moved up
Share of JNJ news events that rose at 30 minutes
+0.06%
Median to close
Where JNJ typically settles by the closing bell
JNJ median reaction to newsJNJ median reaction to news across 2 horizons: 30-min +0.06%, to close +0.06%.30-minto close30-min: +0.06%to close: +0.06%+0.06%+0.06%0+0.06%
Median move vs. the price at the news timestamp, across 2,000+ labeled events.
Where JNJ reactions landvs 2,000+ measured JNJ reactions
JNJMiddle 50% · -0.26% to +0.39%Zero: 0.00%Median: +0.06%Median +0.06%-0.50%0+0.50%
Middle 50% of JNJ reactions-0.26% to +0.39%
Median reaction (30-min)+0.06%
Measured reactions2,000+
Point-in-time · zero look-ahead

Half of all Johnson & Johnson news events land between -0.26% and +0.39% at 30 minutes.

Reaction stats as of 2026-07-14. Newest measured event . Reaction = percent move vs. the price at the news timestamp.

By event type

How JNJ reacts, by analyst action.

EventEventsMedian 30-min% positiveMedian to close
Analyst upgrades40+0.14%60%+0.55%
Analyst downgrades30-0.13%47%+0.22%
Coverage initiations15+0.15%60%+0.45%
Rating reiterations230+0.01%50%-0.03%
Price-target raises73-0.03%45%-0.09%
Price-target cuts23+0.10%61%-0.02%

Last 3 years, pulled 2026-07-14. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how JNJ ranks against every other measured name →

That’s how JNJ usually reacts — get an email when it moves on news →
Next time, know first

Email me when JNJ moves on news.

One email per qualifying move — the headline, the measured reaction, and how it compares to JNJ's baseline. Nothing else.

▲ JNJ Free · unsubscribe anytime
26M+ news records Operating since 2012 Methodology on SSRN ↗
Latest news

Recent JNJ events, each with its measured reaction. (Page 1 of 10.)

DateHeadlineEventSource5-minTo close
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with MenopausePress releaseBusiness Wire-0.33%—
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)Press releasePR Newswire+0.40%-0.57%
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) studyPress releasePR Newswire+0.05%+0.39%
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myelomaPress releasePR Newswire+0.05%+0.42%
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myelomaPress releasePR Newswire-0.08%-0.68%
DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026Press releaseBusiness Wire-0.28%+0.83%
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 studyPress releasePR Newswire+0.67%-0.06%
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026Press releasePR Newswire-0.99%+0.52%
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancerPress releasePR Newswire-0.41%-1.73%
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact LensesPress releaseBusiness Wire-0.16%-1.43%
Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026Press releasePR Newswire-1.57%-0.80%
An AI Wrote a Tell-All. About Itself. When Pressed, it Confessed Everything.Press releasePR Web+1.07%+0.17%
Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare SummitPress releaseBusiness Wire+0.15%+0.40%
Johnson & Johnson to Host Investor Conference Call on Third-Quarter ResultsPress releaseBusiness Wire+0.02%+0.05%
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsPress releasePR Newswire-0.06%+0.78%
Form N-PX JOHNSON & JOHNSON For: Jun 30SEC filing · Form N-PXSEC EDGAR+0.28%-0.39%
Quantified Named One of the Fastest-Growing AI & Data Companies on the Inc. 5000 List for the Second Consecutive YearPress releasePR Web+0.28%-0.39%
Form 13F-HR JOHNSON & JOHNSON For: Jun 30SEC filing · Form 13F-HRSEC EDGAR-0.09%+0.42%
Form 8-K JOHNSON & JOHNSON For: Aug 04SEC filing · Form 8-KSEC EDGAR-1.31%+0.20%
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare ConferencePress releaseBusiness Wire+0.55%+0.92%
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective SeptemberPress releaseBusiness Wire-1.31%+0.20%
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerPress releasePR Newswire+0.15%-1.24%
Form 8-K JOHNSON & JOHNSON For: Jul 29SEC filing · Form 8-KSEC EDGAR+0.15%-1.24%
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune ResetPress releaseBusiness Wire+0.15%-1.24%
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology InnovationPress releaseBusiness Wire+0.15%-1.24%
Form 8-K JOHNSON & JOHNSON For: Jul 27SEC filing · Form 8-KSEC EDGAR+0.64%-1.21%
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc LitigationPress releaseBusiness Wire+0.64%-1.21%
Form 10-Q JOHNSON & JOHNSON For: Jun 28SEC filing · Form 10-QSEC EDGAR-0.52%+0.75%
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myelomaPress releasePR Newswire+1.05%+1.58%
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical SystemPress releaseBusiness Wire+0.02%+1.14%
DePuy Synthes Acquires Expanding Innovations™Press releaseBusiness Wire+0.05%+0.55%
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year AwardPress releaseBusiness Wire+0.05%+0.55%
Form 8-K JOHNSON & JOHNSON For: Jul 15SEC filing · Form 8-KSEC EDGAR+2.13%-0.80%
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026Press releaseBusiness Wire+2.13%-0.80%
Johnson & Johnson reports Q2 2026 results, raises 2026 outlookPress releaseBusiness Wire+2.13%-0.80%
Products That Count Announces Winners of the 2026 Q2 Product Awards in Fintech, Cybersecurity, and HealthcarePress releasePR Web+0.10%+0.18%
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF PlatformPress releaseBusiness Wire-0.34%-1.72%
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravisPress releasePR Newswire+0.15%+0.67%
Form 11-K JOHNSON & JOHNSON For: Dec 31SEC filing · Form 11-KSEC EDGAR+0.68%+2.62%
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, FloridaPress releaseBusiness Wire-2.04%-1.40%
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myelomaPress releasePR Newswire-2.04%-1.40%
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapiesPress releasePR Newswire+0.18%-0.70%
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and PatientsPress releaseBusiness Wire+0.18%-0.70%
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos TrialPress releaseBusiness Wire-0.04%-0.47%
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate PlatformPress releaseBusiness Wire+0.65%-0.26%
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 studyPress releasePR Newswire+0.59%+0.35%
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's diseasePress releasePR Newswire+0.59%+0.35%
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigmPress releasePR Newswire-0.50%+0.14%
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limitedPress releasePR Newswire-0.50%+0.14%
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myelomaPress releasePR Newswire-0.30%-2.55%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Keep exploring

Where else JNJ is measured.

JNJ earnings → · Analyst actions → · SEC filings → · Full history →

Other Health Care names, measured the same way

TickerEventsMedian 30-min% positive
Eli Lilly (LLY)2,000++0.03%52%
UnitedHealth Group (UNH)2,000+-0.03%48%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.

All Healthcare names, measured the same way →

Every ticker we measure the same way24
Method

How the numbers are made.

How is Johnson & Johnson's median reaction calculated?

Every labeled JNJ news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 2,000+ events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.

What counts as a positive reaction?

Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of JNJ's measured events are up at 30 minutes; the rest close the window flat or negative.

How often is this page updated?

The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-07-14.

Does JNJ's past reaction predict its next one?

No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.

Stop guessing what the event means

You just saw one reaction.
There are 26 million more.

For investors

Know the next move, measured.

Ticker alerts with the realized reaction — not the headline spin.

Free · no credit card · unsubscribe anytime
For builders

The dataset, one command away.

claude mcp add news-quantified

Then ask Claude: “how does JNJ react to downgrades?” — or pull it raw via REST.

60-second signup on the NQ portal · 100 free credits/mo
26M+ news records, 2006–2026 Operating since 2012 Point-in-time, zero look-ahead Peer-reviewable methodology (SSRN) ↗